Glucosamine/Chondroitin and Mortality in a US NHANES Cohort

References

1. 1.↵
   National Institutes of Health, National Center for Complementary and Integrative Health. Glucosamine and Chondroitin for Osteoarthritis. September 2017. Available at: https://nccih.nih.gov/health/glucosaminechondroitin#hed1. Accessed March 16, 2020.
2. 2.↵
   1. Wilkens P,
   2. Scheel IB,
   3. Grundnes O,
   4. Hellum C,
   5. Storheim K

   . Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. JAMA 2010;304:45–52.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Sawitzke AD,
   2. Shi H,
   3. Finco MF,
   4. Dunlop DD,
   5. Bingham CO 3rd.,
   6. Harris CL,
   7. et al

   . The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008;58:3183–91.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Sawitzke AD,
   2. Shi H,
   3. Finco MF,
   4. Dunlop DD,
   5. Harris CL,
   6. Singer NG,
   7. et al

   . Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010;69:1459–64.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Reginster JY,
   2. Deroisy R,
   3. Rovati LC,
   4. Lee RL,
   5. Lejeune E,
   6. Bruyere O,
   7. et al

   . Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251–6.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Ma H,
   2. Li X,
   3. Sun D,
   4. Zhou T,
   5. Ley SH,
   6. Gustat J,
   7. et al

   . Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ 2019;365:l1628.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Bell GA,
   2. Kantor ED,
   3. Lampe JW,
   4. Shen DD,
   5. White E

   . Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol 2012;27:593–603.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Navarro SL,
   2. White E,
   3. Kantor ED,
   4. Zhang Y,
   5. Rho J,
   6. Song X,
   7. et al

   . Randomized trial of glucosamine chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One 2015;10:e0117534.

   OpenUrl
9. 9.↵
   1. Yu Z,
   2. Ju Y,
   3. Liu H

   . Anti-lung cancer effect of glucosamine by suppressing the phosphorylation of FOXO. Mol Med Rep 2017;16:3395–400.

   OpenUrl
10. 10.↵
    1. Hu J,
    2. Chen H,
    3. Jia P,
    4. Fang Y,
    5. Liu T,
    6. Song N,
    7. et al

    . Augmented O-GlcNAc signaling via glucosamine attenuates oxidative stress and apoptosis following contrast-induced acute kidney injury in rats. Free Radic Biol Med 2017;103:121–32.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Tannock LR,
    2. Little PJ,
    3. Wight TN,
    4. Chait A

    . Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J Lipid Res 2002;43:149–57.

    OpenUrlAbstract/FREE Full Text